DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Penclomedine is an investigational drug.
There have been 6 clinical trials for Penclomedine. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Neoplasms, Neoplasms, Second Primary, and Brain Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), DEKK-TEC, Inc., and Ochsner Health System.
There are fifty-nine US patents protecting this investigational drug and five hundred and eighteen international patents.
Recent Clinical Trials for Penclomedine
|A Phase I Study of DM-CHOC-PEN in Pediatric and Adolescent Subjects With Advanced Cancers||DEKK-TEC, Inc.||Phase 1|
|Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors||Detroit Clinical Research Center, Farmington Hills, Lansing and Owasso, MI||Phase 2|
|Study of 4-Demethyl-4-cholesteryloxycarbonylpenclome in Patients With Brain Tumors||Icahn School of Medicine at Mount Sinai||Phase 2|
Top disease conditions for Penclomedine
Top clinical trial sponsors for Penclomedine
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Penclomedine||Start Trial||Methods and systems for predicting cancer outcome||H. Lee Moffitt Cancer Center and Research Institute, Inc. (Tampa, FL) University of South Florida (Tampa, FL)||Start Trial|
|Penclomedine||Start Trial||Methods and compositions for the treatment of a host with a cellular proliferative disease||Matrix Pharmaceutical, Inc. (Menlo Park, CA)||Start Trial|
|Penclomedine||Start Trial||Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof||Pharmacia & UpJohn AB (Stockholm, SE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Penclomedine||European Patent Office||1894131||2025-02-25||Start Trial|
|Penclomedine||World Intellectual Property Organization (WIPO)||2005083128||2024-02-25||Start Trial|
|Penclomedine||World Intellectual Property Organization (WIPO)||2006093507||2024-02-25||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|